Scientific article
Open access

Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP

Published inNeurology: Neuroimmunology & Neuroinflammation, vol. 8, no. 5, e1031
Publication date2021

Objective To determine whether CSF interleukin 8 (IL-8) concentration can help to distinguish Guillain-Barré syndrome (GBS) from chronic inflammatory demyelinating polyneuropathy (CIDP) at the initial stage of the disease. Methods We performed retrospective immunoassay of IL-8 in CSF, collected at the University Hospitals of Geneva between 2010 and 2018, from patients diagnosed with GBS (n = 45) and with CIDP (n = 30) according to the Brighton and European Federation of Neurological Societies/Peripheral Nerve Society criteria by a physician blinded to biological results.

Citation (ISO format)
BREVILLE, Gautier et al. Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP. In: Neurology: Neuroimmunology & Neuroinflammation, 2021, vol. 8, n° 5, p. e1031. doi: 10.1212/NXI.0000000000001031
Main files (1)
Article (Published version)
ISSN of the journal2332-7812

Technical informations

Creation07/20/2021 10:48:00 AM
First validation07/20/2021 10:48:00 AM
Update time03/16/2023 1:39:01 AM
Status update03/16/2023 1:39:00 AM
Last indexation02/12/2024 1:31:50 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack